NF1 and neurofibroma: Through previous epidemiological and pathological studies, some scholars have found that 40%–80% of CPT patients are NF-1 gene mutation carriers, and there are neurofibroma-like tissues growing and invading in the diseased periosteum (Carlier et al., 2016; Van Royen et al., 2016).